(Reuters) - The approval follows a regulatory review of a major clinical
study, known as TORCH, into the drug's use among patients with
chronic obstructive pulmonary disease , Glaxo said in a
statement on Monday.
"We hope, and expect, that this will mean that patients
presenting to their healthcare professional start to use
Seretide earlier and benefit from improvements in quality of
life and in their lung function, before they have reached the
severe stage of the disease," Darrell Baker, Glaxo's head of
respiratory medicines development, said.
Read more at Reuters.com Government Filings News
study, known as TORCH, into the drug's use among patients with
chronic obstructive pulmonary disease , Glaxo said in a
statement on Monday.
"We hope, and expect, that this will mean that patients
presenting to their healthcare professional start to use
Seretide earlier and benefit from improvements in quality of
life and in their lung function, before they have reached the
severe stage of the disease," Darrell Baker, Glaxo's head of
respiratory medicines development, said.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment